Latest stories on NPCE
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
StockTitan56 · neutralgeneral
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
StockTitan56 · neutralgeneral
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?
Quartz63 · neutralanalyst
Cantor Fitzgerald reiterates Overweight rating on NeuroPace stock
Investing.com Analyst Ratings61 · neutralanalyst
NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
NeuroPace raises FY26 revenue view to $99.5M-$101.5M from $99M-$101M
The Fly63 · neutralearnings
NeuroPace reports Q2 EPS (18c), consensus (20c)
The Fly38 · neutralearnings
NeuroPace Inc (NPCE) files 8-K
SEC 8-K50 · neutralgeneral
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
StockTitan67 · bullishearnings
NeuroPace drops as bid to expand label for RNS System denied in U.S.
Seeking Alpha38 · neutralgeneral
NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript
Seeking Alpha63 · neutralproduct/pr
NeuroPace's Panel Track Supplement Not Approvable in Current Form, FDA Says
Morningstar34 · bearishgeneral
NeuroPace faces FDA setback on epilepsy label expansion
TipRanks34 · bearishproduct/pr
NeuroPace Inc (NPCE) files 8-K
SEC 8-K50 · neutralgeneral
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
StockTitan63 · neutralproduct/pr
Mizuho initiates NeuroPace stock coverage with outperform rating
Investing.com Analyst Ratings61 · neutralanalyst
NeuroPace, Inc. (NPCE) Reveals FDA Approval of ECoG Assistant™
Yahoo Finance78 · bullishproduct/pr
NeuroPace Inc (NPCE) files 8-K
SEC 8-K50 · neutralgeneral
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care | NPCE Stock News
StockTitan73 · bullishproduct/pr